Hurvitz SA, Bardia A, Quiroga V, Park YH, et al. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol 2023;24:1029-1041.
PMID: 37657462